You are here

  • Home
  • Archive
  • Volume 12, Issue e5
  • Chemotherapy-induced nausea and vomiting from oral chemotherapy for childhood acute lymphoblastic leukaemia: feasibility study

Article Text

Article menu
Download PDFPDF
Short report
Chemotherapy-induced nausea and vomiting from oral chemotherapy for childhood acute lymphoblastic leukaemia: feasibility study
  1. Anja Kovacevic1,
  2. Araby Sivananthan2,
  3. Rikesh Patel2,
  4. Priya Patel2,3,
  5. Ashlee Vennettilli2,
  6. Edric Paw Cho Sing2,3,
  7. Sue Zupanec4,
  8. Sarah Alexander5,
  9. Lillian Sung5 and
  10. L Lee Dupuis1,2,3
  1. 1 Pharmacy, The Hospital for Sick Children, Toronto, Ontario, Canada
  2. 2 Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada
  3. 3 Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
  4. 4 Nursing, The Hospital for Sick Children, Toronto, Ontario, Canada
  5. 5 Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada
  1. Correspondence to Dr L Lee Dupuis, Research Institute, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; lee.dupuis{at}sickkids.ca

Abstract

Objective To evaluate the feasibility of a large prospective trial aimed at improving chemotherapy-induced nausea and vomiting (CINV) control in paediatric patients undergoing oral chemotherapy during acute lymphoblastic leukaemia (ALL) maintenance therapy.

Methods English-speaking children, 4.0–17.99 years old and undergoing ALL maintenance treatment with an English-speaking guardian, were eligible to participate in this observational, serial, cross-sectional feasibility study. Data were collected from participants over one to three 7-day periods during months 2–3, 5–6 and 11–12 of ALL maintenance treatment. A future trial was considered feasible if the mean time to enrol 10 patients in each of three data collection periods was ≤1 year with ≥80% of patients returning evaluable data. CINV control was described as a secondary endpoint.

Results Twenty-nine of 31 consenting patients (median age: 6.5 years, IQR: 5.1–9.2) completed the study: 10 in months 2–3, 10 in months 5–6 and 9 in months 11–12. The total time to recruit 29 patients was 1.2 years. In each of the three data collections periods, 72% of the patients provided evaluable data. Complete CINV control was reported in 6/21 (29%) evaluable study periods.

Conclusions A future trial to evaluate interventions to improve CINV control in patients with ALL undergoing oral maintenance chemotherapy as designed in this study is not feasible. An electronic data capture method and deferring patient recruitment until the mid-maintenance to late-maintenance phase should be considered in the design of a future trial.

  • paediatrics
  • leukaemia
  • nausea and vomiting

Data availability statement

Data are available upon request.

https://doi.org/10.1136/bmjspcare-2019-002022

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data are available upon request.

    View Full Text

    Footnotes

    • Contributors AK, SA, LS and LLD conceived and designed the study; AK, AS, RP, PP, AV, EPCS and SZ collected the data; AK and LLD analysed the data and wrote the paper; AS, RP, PP, AV, EPCS, SZ, SA and LS reviewed the paper and provided critical comments; and AK, AS, RP, PP, AV, EPCS, SZ, SA, LS and LLD reviewed and approved the final submission:

    • Funding The funding support of the Department of Pharmacy, SickKids is gratefully acknowledged.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.